Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. Januar 2023 08:00 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple...
28. September 2022 16:09 ET | Quelle: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Acquires Aceragen

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00...
05. November 2017 08:30 ET | Quelle: Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting

HAYWARD, Calif., Nov. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present additional findings from the CHABLIS-SC1, Phase 3 clinical study of blisibimod, a novel...